Battling the two-headed dragon of prostate cancer targeted therapy

Neoadjuvant intense androgen deprivation therapy for high-risk localized prostate cancer is an emerging but unproven treatment paradigm that is hoped to delay or prevent disease recurrence. We found that a patient enrolled in a clinical trial harbored two completely independent prostate cancers that...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilkinson, Scott, Sowalsky, Adam G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Author's Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469682/
https://www.ncbi.nlm.nih.gov/pubmed/32944614
http://dx.doi.org/10.1080/23723556.2020.1745037
_version_ 1783578447019245568
author Wilkinson, Scott
Sowalsky, Adam G.
author_facet Wilkinson, Scott
Sowalsky, Adam G.
author_sort Wilkinson, Scott
collection PubMed
description Neoadjuvant intense androgen deprivation therapy for high-risk localized prostate cancer is an emerging but unproven treatment paradigm that is hoped to delay or prevent disease recurrence. We found that a patient enrolled in a clinical trial harbored two completely independent prostate cancers that responded differently to this therapy.
format Online
Article
Text
id pubmed-7469682
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-74696822020-09-28 Battling the two-headed dragon of prostate cancer targeted therapy Wilkinson, Scott Sowalsky, Adam G. Mol Cell Oncol Author's Views Neoadjuvant intense androgen deprivation therapy for high-risk localized prostate cancer is an emerging but unproven treatment paradigm that is hoped to delay or prevent disease recurrence. We found that a patient enrolled in a clinical trial harbored two completely independent prostate cancers that responded differently to this therapy. Taylor & Francis 2020-04-14 /pmc/articles/PMC7469682/ /pubmed/32944614 http://dx.doi.org/10.1080/23723556.2020.1745037 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Author's Views
Wilkinson, Scott
Sowalsky, Adam G.
Battling the two-headed dragon of prostate cancer targeted therapy
title Battling the two-headed dragon of prostate cancer targeted therapy
title_full Battling the two-headed dragon of prostate cancer targeted therapy
title_fullStr Battling the two-headed dragon of prostate cancer targeted therapy
title_full_unstemmed Battling the two-headed dragon of prostate cancer targeted therapy
title_short Battling the two-headed dragon of prostate cancer targeted therapy
title_sort battling the two-headed dragon of prostate cancer targeted therapy
topic Author's Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469682/
https://www.ncbi.nlm.nih.gov/pubmed/32944614
http://dx.doi.org/10.1080/23723556.2020.1745037
work_keys_str_mv AT wilkinsonscott battlingthetwoheadeddragonofprostatecancertargetedtherapy
AT sowalskyadamg battlingthetwoheadeddragonofprostatecancertargetedtherapy

Ejemplares similares